Innovative Diagnostic Technology Naveris specializes in molecular diagnostics with proprietary tests like NavDx that detect viral-associated cancers using blood and saliva samples, positioning it as a leader in precision oncology diagnostics.

Growing Clinical Adoption The NavDx test is actively used at prominent cancer treatment centers and academic medical institutions across the U.S., reflecting strong validation and increasing demand for advanced cancer detection solutions.

Recent Market Expansions With the launch of NavDx for Molecular Residual Disease detection and ongoing clinical studies such as DART 2.0, Naveris is expanding its product portfolio and clinical validation scope, opening opportunities within oncology and healthcare providers.

Strategic Collaborations Partnerships with Mayo Clinic and participation in clinical trials position Naveris as a key player in research-driven diagnostics, increasing its visibility among medical institutions seeking innovative cancer detection tools.

Financial Momentum With recent funding of over 17 million dollars and revenue estimates between 25 to 50 million dollars, Naveris is financially equipped to accelerate sales efforts and expand its market reach within the growing molecular diagnostics industry.